News | Heart Valve Technology | October 18, 2022

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

Smaller Sheath Simplifies Access and Improves Ease-of-Use

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set.

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set. 

 


October 18, 2022 —  The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement of Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr. As a result of its smaller size and other technological advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, reduce procedural steps and help improve outcomes. 

The Low Profile Sheath is the first sheath specifically engineered to be compatible with the Impella single-access technique, which removes the need for an additional access site. Additionally, it is designed to: 

Simplify access and ease-of-use by eliminating the peel-away sheath and the need for the re-access sheath for patients who are sent to the intensive care unit. 

Further minimize vascular complications and bleeding. 

Facilitate easier delivery into the vasculature with a hydrophilic coated long-taper dilator, reducing the need for multiple steps of serial dilation. 

Facilitate easier management of the patient during heart pump removal and vascular closure because Impella can be removed directly from the sheath without re-wiring. 

“Abiomed’s Low Profile Sheath is a game changing technological achievement that will further improve patient outcomes by making it even easier for physicians to insert, manage and remove Impella heart pumps,” said Chuck Simonton, MD, Abiomed’s chief medical officer. 

Abiomed will begin a phased roll-out of the Impella Low Profile Sheath this quarter. 

For more information: www.abiomed.com


Related Content

News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 18, 2024 – Astellas Pharma Inc. recently announced that Digitiva, a non-invasive digital health solution for heart ...

Home September 19, 2024
Home
News | Heart Failure

Aug. 21, 2024 — The incidence rate of heart failure was 2- to 3-fold higher among American Indian populations than rates ...

Home August 21, 2024
Home
News | Heart Failure

July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & ...

Home July 31, 2024
Home
News | Heart Failure

July 30, 2024 — Patients with congestive heart failure (CHF) having a compromised blood supply, are at greater risk of ...

Home July 30, 2024
Home
News | Heart Failure

July 29, 2024 — When it comes to treating cardiac arrest, acting quickly can mean the difference between life and death ...

Home July 29, 2024
Home
News | Heart Failure

June 27, 2024 — The human body has sophisticated defenses against the deposition of calcium minerals that stiffen heart ...

Home June 27, 2024
Home
News | Heart Failure

June 24, 2024 — Endotronix, Inc., a privately held company dedicated to advancing the treatment of heart failure (HF) at ...

Home June 24, 2024
Home
News | Heart Failure

June 18, 2024 — As we commemorate Juneteenth 2024, JACC, the flagship journal of the American College of Cardiology, has ...

Home June 18, 2024
Home
Subscribe Now